A RANDOMIZED, PROSPECTIVE MULTICENTER PHARMACOEPIDEMIOLOGIC STUDY OF CYCLOSPORINE MICROEMULSION IN STABLE RENAL GRAFT RECIPIENTS1,2,3

MeCsA appears to be a safe and effective therapy in stable renal transplant patients and provides superior and more consistent absorption of cyclosporine when compared with ConCsA. Transient toxicity after conversion to MeCsA occurs in some patients, and may reflect the increased exposure to cyclosporine. Use of a limited sampling approach combining trough and 2-hr postdose concentrations may provide an effective way to monitor this exposure.